Medication Adherence is defined as the right medicine, in the right dosage, at the right time.
Despite the many effective medicines for chronic conditions discovered through modern scientific research, adherence to their long-term therapies in developed countries averages only fifty-percent. Poor adherence not only wastes resources, it limits the possibilities for good patient outcomes and improved quality of life. A leading cause of preventable morbidity and mortality, it costs the health care system billions of dollars every year.
Pharmacists have the ability to play a vital role in ensuring proper adherence in their patients, given their accessibility in their communities and reputation as trusted health care professionals.
This mutually-accepted principle has inspired the partnership between Pharmaceutical Sciences at UBC and the global, research-based biopharmaceutical company, AbbVie Corporation, in the creation of the AbbVie Professorship in Medication Adherence.
The role of the Professorship is to identify barriers to proper adherence, and to develop methodologies that will help pharmacists identify and overcome those obstacles. A strong, innovative multi-disciplinary program of research in adherence will focus on the role of pharmacists, independently and in collaboration with other health care disciplines. Supporting the Professorship is the Faculty’s new Pharmacists Clinic that will provide a “living laboratory” for testing of adherence methodologies and practical experience in their implementation among students and practitioners.
Dr. Mary De Vera, a UBC alumna and health services researcher with expertise in pharmacoepidemiology, was appointed July 1 2013 as the inaugural holder of the Professorship.
Pharmaceutical Sciences at UBC is pleased to collaborate with AbbVie to find sustainable health care solutions and to help patients achieve better health outcomes and live healthier lives.